Below is a list of all AbbVie clinical trials in Canada that you or someone you know might be interested in joining. Find what you’re looking for by using the filters to narrow down the results. You can also see the full list of conditions in which AbbVie deals here.
The purpose of this study is to describe the impact of treatment with an active drug on work related productivity and economic burden in patients with Rheumatoid Arthritis (RA) treated in Canada.
The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with an active drug versus placebo and versus an active comparator, an active drug, in adults with with moderately to severely active rheumatoid
The objectives of Period 1 were the following:
1. To compare the safety and efficacy of an active drug 7.5 mg once daily (QD) monotherapy (for participants in Japan only), 15 mg QD monotherapy, and 30 mg QD monotherapy versus weekly methotrexate
The primary objectives of this study are to compare the efficacy, safety, and tolerability of an active drug 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and symptoms of adults with moderately to severely active rheumatoid
The study objective of Period 1 (Day 1 to Week 24) is to compare the safety and efficacy of 30 mg once daily (QD) and 15 mg QD an active drug versus placebo for the treatment of signs and symptoms of participants with moderately to severely active RA who
<p>This is a long-term extension (LTE) study to assess the safety, tolerability and efficacy of an active drug and an active drug in Rheumatoid Arthritis (RA) participants who have completed M16-063</p>
This is a phase 2 study to evaluate safety and efficacy of a combination of active drugs vs placebo on a background of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDS) for the treatment of signs and symptoms of Rheumatoid Arthritis
The comparison of safety and efficacy of an active drug versus abatacept in participants with rheumatoid arthritis on a stable background conventional synthetic Disease Modifying Anti-Rheumatic Drug (csDMARD) who have an inadequate response or intolerance
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. This study will assess how effective Upadacitinib is in changing the disease symptoms in Canadian participants with RA
The primary objective of the study was to investigate the association between residual disease activity at Baseline as detected by Magnetic Resonance Imaging (MRI) and the occurrence of flares in participants with rheumatoid arthritis (RA) randomized to